Skip Navigation

Cardiovascular Research 2002 53(3):605-619; doi:10.1016/S0008-6363(01)00466-7
© 2002 by European Society of Cardiology
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mikkola, T. S
Right arrow Articles by Clarkson, T. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikkola, T. S
Right arrow Articles by Clarkson, T. B
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Estrogen replacement therapy, atherosclerosis, and vascular function

Tomi S Mikkolaa,b and Thomas B Clarksona,*

aComparative Medicine Clinical Research Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1040, USA
bDepartment of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki 00290, Finland

tclarkso{at}wfubmc.edu

* Corresponding author. Tel.: +1-336-716-1570; fax: +1-336-716-1601

Received 7 June 2001; accepted 13 September 2001


   Abstract
Top
 Abstract
1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
There is strong evidence from both human and nonhuman primate studies supporting the conclusion that estrogen deficiency increases the progression of atherosclerosis. More controversial is the conclusion that postmenopausal estrogen replacement inhibits the progression of atherosclerosis. Estrogen treatment of older women (>65 years) with pre-existing coronary artery atherosclerosis had no beneficial effects. In contrast, estrogen treatment of younger postmenopausal women or monkeys in the early stages of atherosclerosis progression has marked beneficial effects. Whether progestogens attenuate the cardiovascular benefits of estrogen replacement therapy has been controversial for more than a decade. Current evidence from studies of both monkeys and women suggest little or no attenuation of estrogen benefits for coronary artery atherosclerosis. Lack of compliance with estrogen replacement therapy, usually because of fear of breast cancer, remains a major problem. Future regimens may overcome that fear by the co-administration of a breast cancer preventive agent (i.e., selective estrogen receptor modulators, phytoestrogens) with low dose estrogen.

KEYWORDS Atherosclerosis; Endothelial function; Hormones; Infection/inflammation; Lipid metabolism


   1. Introduction
Top
 Abstract
 1. Introduction
2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
The cardiovascular diseases remain the largest cause of morbidity and mortality among postmenopausal women in westernized societies. The advantages/disadvantages of estrogen replacement following menopause are public health issues of major importance, given the rapidly increasing numbers of postmenopausal women and the fact that the average life span now extends to about 35 years beyond normal ovarian function. A decade ago, a consensus had emerged that postmenopausal estrogen replacement markedly reduced the burden and mortality associated with coronary heart disease. Today, many question that consensus because two randomized prospective trials with coronary heart disease patients failed to find benefits from estrogen replacement.

In this review, we attempt to place in context the comparative, experimental, and clinical data on estrogen replacement therapy and cardiovascular disease. Particularly, we make an effort to interpret the negative clinical trials in view of observational and experimental data. Further, we present our best thoughts about future directions.


   2. What is the evidence that endogenous estrogen modulates cardiovascular disease?
Top
 Abstract
 1. Introduction
 2. What is the...
3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
Among premenopausal women, coronary heart disease is extremely rare, even in high-risk populations [1], and the overall incidence of cardiovascular complications is much lower in premenopausal women than in men of similar age [2]. After menopause, the reduced risk for coronary heart disease in women is gradually lost, and this female protection is more accurately characterized as a delay in disease onset, with the incidence curve for women lagging behind that of men 5–10 years [3]. The most plausible explanation for these observations is the protective effect of endogenous female sex steroids, particularly estrogens, during premenopausal years. This is supported by the initial Framingham Study, which showed that the cardiovascular incidence rates were lower in premenopausal than postmenopausal women [4]. Although the number of person–years during the 20 years of observation in this study was nearly the same for premenopausal and postmenopausal status, there were significantly more cardiovascular events among postmenopausal women compared to premenopausal women of the same age.

In western populations, the average age at menopause is about 51 years [5]. Premature menopause, natural or surgical, with reduced lifetime exposure to endogenous estrogens, should result in increased risk of coronary heart disease based on the assumption that estrogen is cardioprotective. Most of the early studies in women who experienced an early menopause show increased risk of heart disease; nevertheless, some of the results are inconsistent and not statistically significant [2]. Potentially, this could be due to small sample size and variability in the study settings in some of the early investigations. The Framingham Study reported that women experiencing natural menopause between ages 45 and 49 years or a surgical menopause between ages 40 and 44 years were more likely to develop coronary heart disease than premenopausal women of the same age [4]. The Nurses' Health Study found no significant association between time since natural menopause and cardiovascular disease, but found increased risk of cardiovascular disease in women with bilateral oophorectomy without estrogen replacement compared to oophorectomized women receiving estrogen replacement therapy [6]. However, a more recent evaluation of the Nurses' Health Study, where analysis was restricted to naturally postmenopausal women who had never used estrogen replacement, found an overall significant association between younger age at menopause and higher risk of coronary heart disease [7]. Similar results were reported in a study with a 29-year follow-up of postmenopausal women, assessing the relationship between age at natural menopause and mortality from ischemic heart disease [8]. Another study investigating a cohort of postmenopausal women aged 50–65 years at enrollment and followed up to 20 years, showed that the risk of cardiovascular mortality was higher for women with early menopause than for those with late menopause [9].

Recently, in a population-based study, Joakimsen et al. found a significant inverse relationship between the age at menopause and both the prevalence and extent of carotid atherosclerosis assessed by ultrasound in 2588 postmenopausal women [10]. Thus, a substantial body of evidence suggests that endogenous estrogen in premenopausal women provide protection against cardiovascular disease.


   3. What is the evidence that estrogen replacement therapy modifies the progression of atherosclerosis?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
3.1. Observational data
A large body of observational data suggests that women using postmenopausal estrogen replacement therapy (ERT) have lower risk for coronary heart disease [11,12]. The most comprehensive observational study is the Nurses' Health Study published first in 1985 [13] and updated in 1991 [14], 1996 [15], and recently in 2000 [16]. The Nurses' Health Study began in 1976 when 121 700 female nurses 30–55 years of age completed a mailed questionnaire about their postmenopausal hormone use and medical history. In the latest report, with 70 533 postmenopausal women followed for up to 20 years, were identified 953 nonfatal myocardial infarctions, 305 coronary deaths, 767 strokes (432 ischemic, 174 hemorrhagic, and 161 other or unspecified type), and 119 deaths due to stroke [16]. Overall, current use of hormone replacement therapy was associated with relative risk for major coronary event of 0.61 (confidence interval (CI), 0.52–0.71) when adjusted for age and the common cardiovascular risk factors (Fig. 1). Surprisingly, longer duration of hormone use was associated with less coronary benefit than short-term use; the relative risk increased from 0.4 for less than 1 year of current use to 0.7 for 10 or more years. As in previous reports from the Nurses' Health Study, risk for ischemic stroke, but not hemorrhagic stroke, was increased slightly among hormone users compared with never-users (relative risk, 1.26; CI, 1.00–1.61).


Figure 1
View larger version (31K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Multivariate adjusted relative risk for coronary heart disease±95% confidence interval (CI). Adjusted for age, body mass index, history of diabetes, hypertension, high cholesterol level, age at menopause, cigarette smoking, and parental history of premature heart disease [16].

 
Although the evidence from the observational studies indicating beneficial effect of ERT on coronary heart disease is consistent, there are several potential sources of bias that might account for these findings. Women who take estrogen tend to be more educated and of higher social class, and have more favorable lifestyles, reduced levels of several heart disease risk factors, and less diabetes than untreated women [12]. Matthews et al. reported that women who elect to take estrogen after the menopause had more favorable levels of multiple coronary risk factors before the menopause than women who chose not to take estrogen [17]. Thus, some of estrogen's putative benefits might be spurious, reflecting ‘a healthy woman effect’. Women who take estrogen are also an unusually compliant subset of all women [18], and in randomized, double-blind, clinical trials, good compliance has been shown to reduce risk of coronary events 40–60%, even when the medication is placebo [19,20]. Obviously, adherence to placebo treatment is not causing this benefit but is a marker for unconsidered factors that result in better coronary outcomes. Thus, randomized, placebo-controlled studies are needed to confirm the beneficial effects of estrogens on the cardiovascular system shown by the observational studies.

3.2. Randomized studies with non-human primates
To overcome the general problems faced with the observational human studies as described above, and the fact that a truly randomized, placebo-controlled, ERT trial in women is difficult to carry out in practice [21], the surgically menopausal female cynomolgus macaque monkey model is useful in evaluating the cardioprotective aspects of ERT [22]. This animal model is often used since these monkeys share with humans DNA greater than 90% homology, and their hormonal profile resemble those of women; distinct menarche, 28-day menstrual cycles, and menopause. Premenopausal macaques also have higher high-density lipoprotein (HDL) cholesterol levels than do male macaques, and females develop fewer coronary artery atherosclerotic lesions. Likewise, postmenopausal cynomolgus macaques have decreased HDL cholesterol concentrations compared to their premenopausal counterparts and increased progression of coronary artery atherosclerosis. Surgical menopause, combined with a moderately atherogenic diet, produces progressive atherosclerosis that is responsive to ovarian hormone replacement.

Direct evidence for a beneficial effect of ERT on progression of coronary artery atherosclerosis was found in the results of a study from Adams et al. [23]. In this study, ovariectomized monkeys that were treated for 30 months with parenterally administered 17β-estradiol showed approximately 50% reduction in coronary artery atherosclerosis compared to the control animals. These findings were confirmed in a subsequent 30-month study evaluating the effects of continuous oral conjugated equine estrogen (CEE) treatment on coronary artery atherosclerosis [24]. Oral CEE treatment caused a 72% reduction in coronary artery plaque size relative to untreated, estrogen-deficient controls. These studies strongly support the observational findings that estrogens are cardioprotective.


   4. Are the cardiovascular benefits of estrogen replacement therapy altered by the stage of atherosclerosis?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
Results from two randomized prospective secondary prevention trials are challenging the conviction that postmenopausal ERT provides cardiovascular benefits. The first, the Heart and Estrogen/Progestin Replacement Study (HERS), determined whether daily treatment with 0.625 mg CEE and 2.5 mg medroxyprogesterone acetate (MPA) would reduce coronary heart disease events in postmenopausal women [25]. This study recruited 2763 women who were generally beyond 65 years of age and had pre-existing coronary heart disease. No reduction in coronary events could be shown by the hormone treatment during an average of 4.1 years of follow-up. In fact, during the first year of the trial, there was an increase in events (relative risk, 1.52; CI, 1.0–2.29), mostly seen in the first 4 months. After 2 years of treatment, there was a tendency toward risk reduction, strongest in the 4th year (relative risk, 0.67; CI, 0.43–1.04). It remains to be seen whether continuation of the trial beyond the four years will reveal significant reduction of coronary events in the treatment group.

In the second study, The Estrogen Replacement Atherosclerosis (ERA) Trial, Herrington and colleagues examined the effect of postmenopausal hormone therapy on the progression of existing coronary artery atherosclerosis as assessed by angiography [26]. The average age of the 309 women in the study was 65 years, and half had experienced a previous myocardial infarction. After 3.5 years of daily treatment with 0.625 mg CEE alone, CEE combined with 2.5 mg MPA, or placebo, repeated angiography did not detect any differences in disease progression between any of the treatment groups.

The Women's Health Initiative (WHI) is a large, ongoing, randomized study evaluating the effects of hormone replacement therapy in postmenopausal women [27]; this study is scheduled for completion in 2005. Although WHI recruited generally healthy postmenopausal women with the intention to evaluate primary prevention, many of the subjects are relatively older women who began treatment years after menopause. Recently, the women in WHI were informed by the Data and Safety Monitoring Board that "during the first 2 years there was a small increase in the number of heart attacks, strokes, and blood clots in women taking active study pills compared to inactive placebo pills", but recommended that the study continue. Thus, the preliminary data from the first years of WHI are similar as seen in the 1st year of HERS [25].

In attempting to understand the incongruity between some of the observational data on human subjects, the results of HERS and ERA, the preliminary data of WHI, and the data on non-human primates, one must sharpen the definition of ‘primary prevention’ and ‘secondary prevention’. These terms have different meanings for vascular biologists and cardiologists. To the vascular biologists, primary prevention of atherosclerosis means to prevent the progression of artery wall fatty streaks to atherosclerotic plaques. As cardiologists have used the term, primary prevention means to interfere with the progression of complicated atherosclerotic plaques to clinical coronary heart disease events. Clinical trials with coronary event endpoints can include subjects that vary markedly at the vascular wall level. Thus, it is possible that the 1st year results of HERS, as well as the preliminary data of WHI, are due to subgroups of women that have more complicated coronary atherosclerosis, perhaps susceptible to some yet to be defined effect of estrogen on plaque remodeling and destabilization, leading to propensity of plaque rupture and thrombosis.

In reconsidering several of the studies with cynomolgus monkeys, we arbitrarily divided them into three life stages (Fig. 2). In life stage 1 the monkeys had little or no atherosclerosis before being made surgically menopausal. Immediately after ovariectomy, CEE treatment was given together with the atherogenic diet. In studies that were carried out with monkeys at life stage 1, there was an average inhibition of coronary artery atherosclerosis of about 70% [24,28,29]. In life stage 2, the monkeys were allowed to develop a moderate amount of atherosclerosis premenopausally before they were made surgically menopausal. CEE treatment was given immediately after ovariectomy and the atherogenic diet continued. In that situation the degree of inhibition of coronary artery atherosclerosis was reduced from 70 to 50% [30]. Finally, in the life stage 3, the animals had little or no atherosclerosis premenopausally, were ovariectomized to make them surgically menopausal, were given an atherogenic diet, but there was a delay of 2 years (equivalent to approximately six years in human life) before CEE treatment was started. Given that postmenopausal delay in initiating the estrogen replacement therapy, no inhibition in the extensiveness of coronary artery atherosclerosis was observed [31]. Taken together, these studies would suggest that estrogens have beneficial effects in the early stages of atherogenesis but have little or no beneficial effects in the final stages of plaque complications, instability and coronary heart disease events.


Figure 2
View larger version (41K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 The relation of pre- and post-menopausal conditions to the degree of, or lack of, inhibition of coronary artery atherosclerosis [24,28,30,31]. OVX, ovariectomy; and CEE, conjugated equine estrogen.

 

   5. Are the cardiovascular benefits of estrogen replacement therapy altered by progestogens?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
Coadministration of a progestogen with ERT is necessary for postmenopausal women with an intact uterus to prevent endometrial hyperplasia and cancer [32]. The influence of added progestogens on the risk for cardiovascular disease is still subject to debate. The relatively few observational studies that evaluate treatment with estrogen combined with progestogen on the risk for coronary heart disease show comparable protective effects as with unopposed estrogen [15,16,33,34]. In most of these studies CEE was combined with MPA in sequential regimens, but also estradiol combined with levonorgestrel was shown to reduce the risk of acute myocardial infarction as effectively as CEE alone [33]. The recent update on The Nurses' Health Study shows similar risk reduction for coronary heart disease among women taking CEE alone (relative risk, 0.55; CI, 0.45–0.68) and those taking CEE plus MPA (relative risk, 0.64; CI, 0.49–0.85) [16]. These results are consistent with those in the previous report from this study [15]. However, there was a 45% higher risk for stroke among women taking CEE plus MPA than in those who had never taken hormone therapy (relative risk, 1.45; CI, 1.10–1.92), while little association was demonstrated between stroke and the use of CEE alone (relative risk, 1.18; CI, 0.95–1.46) [16]. Because of the rather wide confidence intervals it is unclear whether this is a real difference.

After the null effect of CEE plus MPA on the secondary prevention of coronary heart disease in HERS [25], it was further suggested that continuous MPA could attenuate the favorable effects of estrogen on atherosclerosis. The possibility of distinction between different types of progestogens, and sequential versus continuous progestogen treatment, is intriguing. In a study with cynomolgus monkeys receiving no treatment, continuous estradiol, or continuous estradiol plus cyclically administered progesterone (28 days on, 28 days off) for 30 months, animals in both treatment groups exhibited approximately one half of the amount of coronary artery atherosclerosis as compared with control animals [23]. In this study, the degree of atherosclerosis with combined treatment was not significantly different from that with estradiol alone, suggesting that progesterone did not attenuate the atheroprotective effects of estradiol (Fig. 3a). Another study with monkeys investigated the effect of continuous oral CEE (human equivalent to 0.625 mg/day), MPA (human equivalent to 2.5 mg/day), or CEE continuously combined with MPA, as opposed to no treatment [24]. After 30 months, unopposed CEE treatment resulted in a 72% reduction in coronary artery atherosclerosis compared to controls, while animals that received MPA, or CEE plus MPA did not differ significantly from controls (Fig. 3b). Plasma lipoprotein concentrations were affected by treatments; however, this did not account for the differential effects of CEE as opposed to CEE plus MPA on coronary artery atherosclerosis. In a most recent study by Clarkson et al. [29] where monkeys were treated for 24 months with CEE or CEE plus MPA in a similar manner as in the previous study [24], there was approximately 62% reduction in coronary artery atherosclerosis in both treatment groups compared to controls (Fig. 3c). Thus, in this study, MPA did not attenuate the atheroprotective effects of CEE. A possible explanation for the differences in the outcome of these two studies may be that in the study by Adams et al. [24], the treatments were given to the animals as a part of the diet once a day, while in the more recent study, the treatments were given in divided doses twice a day [29]. By studying the endometrium of the animals in these two studies by Ki67 labeling, a marker of cell proliferation, it appeared that giving the MPA as a single dose was more effective in inhibiting endometrial proliferation than giving the MPA in two divided doses [35]. Therefore, it seems the estrogenic stimulus was higher and the progestogenic effect reduced in the study by Clarkson et al. compared to that by Adams et al. The differences between the two studies might suggest that when MPA is given at a dose that has the desired antagonistic effect on the endometrium, it attenuates the cardiovascular benefits of CEE, but if the progestogenic potency is reduced, the undesirable effects on atherogenesis are also reduced. Taken together, it is possible that all progestogens are not alike with regard to their influence on estrogen-induced cardioprotection, which perhaps more importantly is affected by the dose of the progestogen. However, further studies are needed to determine how progestogens alter the cardiovascular benefits of ERT.


Figure 3
View larger version (21K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 3 Estrogen replacement therapy vs. hormone replacement therapy in primary prevention of coronary artery atherosclerosis of postmenopausal cynomolgus monkeys. Data are means±standard errors adjusted for baseline differences in plasma lipid concentrations. (Panel a) Modified from Adams et al. (1990) [23]; (Panel b) modified from Adams et al. (1997) [24]; (Panel c) modified from Clarkson, Anthony and Wagner, submitted [29]. E2, estradiol; P, progesterone; CEE, conjugated equine estrogen; and MPA, medroxyprogesterone acetate.

 

   6. What are the lipid-dependent and -independent effects of estrogen replacement therapy on the cardiovascular protection?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
6.1. Plasma lipids and lipoproteins
Dyslipidemia is associated with increase risk of atherosclerosis in both men and women. Lipoprotein concentrations among premenopausal women differ from men; total and low-density lipoprotein (LDL) cholesterol are lower while HDL cholesterol is higher [36,37]. After menopause, women lose this beneficial lipid profile when total and LDL cholesterol become higher and HDL cholesterol falls [36–39]. Estrogen replacement therapy has, however, the potential to restore the premenopausal lipid profile in women. The effects of estrogen on lipids and lipoproteins depend on the type and dose of estrogen used, and its route of administration.

Oral estrogen regimens have been shown to increase plasma triglycerides, HDL cholesterol and apoA1 levels, while decreasing LDL cholesterol and lipoprotein (a) [Lp(a)] levels [40–43]. Estrogen therapy increases triglyceride levels primarily by increasing the production of large, very-low-density lipoprotein particles, most of which are cleared by the liver rather than being converted to small and more atherogenic very-low-density lipoprotein particles or LDL [40]. Thus, the atherogenic potential of estrogen-induced hypertriglyceridemia may be of little concern. In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, 875 healthy postmenopausal women aged 45–65 years were studied for 3 years using a randomized, double-blind protocol [43]. The group receiving oral CEE (0.625 mg/day) had a 10–12% decrease in LDL cholesterol levels, and a similar increase in HDL cholesterol levels during the study. In the PEPI trial, Lp(a) concentrations, shown to be an independent predictor of the risk of coronary heart disease in women [44], were reduced by 25% on average among women treated with CEE, with or without the addition of a progestogen [45]. Neither the addition of MPA nor micronized progesterone to CEE affected the decreases in LDL levels, but MPA diminished the beneficial increases in HDL, while micronized progesterone did not attenuate HDL increases associated with CEE [43]. In healthy postmenopausal women, treatment with continuous oral combined 17β-estradiol plus norethisterone acetate or continuous oral 17β-estradiol plus intermittent norgestimate show favorable effects on both lipid and lipoprotein concentrations [46]. In another study where postmenopausal women were treated for 3 months with 0.625 or 1.25 mg/day oral CEE, LDL concentrations were decreased by 15 and 19%, respectively, while HDL concentrations were increased by 16 and 18%, respectively [40]. In this study also, oral micronized estradiol (2 mg/day) was investigated revealing similar results, decreasing LDL concentrations by 14% and increasing HDL concentrations by 15% [40]. Transdermal route of estrogen delivery has been reported to result in trivial beneficial changes [47,48] or no changes [40,49] in plasma LDL and HDL concentrations. The fact that transdermally-administered estrogen has less of an effect on serum lipids and lipoproteins is due to the bypass of the portal circulation and thus, minimal effect on hepatic metabolism [50].

Clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are effective in reducing cardiovascular-related morbidity and mortality [51,52]. Statins lower LDL cholesterol to a greater degree than estrogen therapy in postmenopausal women, but statins have a lesser effect on HDL cholesterol and Lp(a) levels than estrogen treatment [53]. In a study where CEE (0.625 mg/day) and simvastatin (10 mg/day) therapies were combined, LDL cholesterol was lowered to a greater degree than either therapy alone, with elevation of HDL cholesterol similar to that of estrogen alone [54]. Lp(a) levels were reduced with therapies including CEE but not with simvastatin alone. In another study, CEE (0.625 mg/day) and simvastatin (5 mg/day) combined therapy had an additive effect on reducing the plasma total cholesterol concentration, and concentrations of large and small LDL cholesterol particles [55] (Fig. 4). HDL cholesterol concentrations were elevated to the same extent in all treatment groups, and combination therapy prevented an estrogen-induced increase in triglyceride concentrations. A randomized, double-blind, cross-over study compared, in 6-week treatment periods, CEE plus MPA, lovastatin (20 mg/day), or a combination of these two, and concluded that the combination therapy resulted in a greater decrease in LDL cholesterol levels and a greater increase in HDL cholesterol, levels than either treatment alone [56]. Clinical trials are needed to determine whether estrogen combined with statins also may have an additive effect in reducing coronary artery atherosclerosis.


Figure 4
View larger version (19K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 4 Effect of ERT Alone, Simvastatin Alone and ERT and Simvastatin in Combination on Plasma Lipoprotein Cholesterol Concentrations. ERT 0.625 mg CEE/day; Simvastatin 5 mg/day. * P<0.05, ** P<0.01, *** P<0.001 [55]. ERT, estrogen replacement therapy; CEE, conjugated equine estrogen; Total-C, Total cholesterol; HDL2-C, high-density lipoprotein2 cholesterol; LDL1-C, low-density lipoprotein1 cholesterol; and LDL2-C, low-density liporprotein2 cholesterol.

 
6.2. Lipid-independent effects
Changes in plasma lipid levels are thought to account for only 25–50% of the overall estrogen-mediated cardiovascular protection [57,58]. Thus, lipid-independent direct actions of estrogen on the blood vessel wall may contribute substantially to the cardioprotective effects of estrogen. Steroid actions are generally mediated by specific receptors, which act as transcription factors, regulating gene expression when activated by steroid binding. Two subtypes of the estrogen receptor (ER) have been identified, the classical ER-{alpha} [59] and the more recently discovered ER-β [60]. Both receptors are expressed in the human [61–64] and non-human primate [65] vascular cells, although the function of these two receptor subtypes at the vascular level has not yet been defined fully. In fact, both ER-{alpha} [66] and ER-β-deficient mice [67] respond to estrogen-mediated vasoprotection after vascular injury, suggesting that there may be an overlap between the actions of the two receptors, or that an undefined receptor for estrogen exists that mediates the vasoprotective effects of estrogen. A recent study with apoE-deficient female mice with or without ER-{alpha} demonstrated that ER-{alpha} is a major mediator of the atheroprotective effect of 17β-estradiol, although existence of ER-{alpha}-independent atheroprotection was also observed [68]. Furthermore, consistent with this, a disruptive mutation of ER-{alpha} in a young man was associated with endothelial dysfunction [69] and premature coronary artery atherosclerosis [70].

Estrogen treatment may act directly at the vascular wall level by affecting endothelial function and vascular tone [58,71]. The effect of estrogen on coronary artery reactivity has been evaluated by repeated quantitative angiography in ovariectomized cynomolgus monkeys [72,73]. Changes in the coronary artery diameter were measured after intracoronary infusion of acetylcholine, which induces endothelium-mediated vasodilatation in normal arteries and constriction in atherosclerotic arteries. After long-term [72] and short-term [73] estrogen treatment, the animals exhibited vasodilatation in response to acetylcholine, whereas estrogen-deficient controls exhibited vasoconstriction. Similar effects have been shown later in both atherosclerotic [74–76] and healthy [76] coronary arteries from estrogen-treated postmenopausal women. In addition to the studies with acetylcholine-induced vasomotion, estrogen treatment induces an increase in flow-mediated vasodilatation of the brachial artery in postmenopausal women [77,78], and this increase may be even greater in women who are hypertensive [79]. Furthermore, a randomized clinical trial comparing oral and transdermal hormone replacement therapy in postmenopausal women evaluated blood flow velocity and peripheral vascular impedance by Doppler [80]. Both regimens reduced impedance to flow in the carotid and uterine arteries, while this reduction became detectable within the first 2 months of treatment and increased further over 6–12 months.

The effects exerted by estrogens on the vascular wall tone may be produced, after long-term treatment, by typical transcriptional ‘genomic’ regulation, but also rapidly after short-term exposure to estrogens, generally described as a ‘non-genomic’ mechanism [58,71]. Long-term estrogen treatment may direct the production of endothelium-derived vasoactive agents, nitric oxide, prostacyclin and endothelin-1 toward vasodilatory direction [81]. Although the relevance of plasma measures of these locally acting vasoactive agents has been questioned, ERT in postmenopausal women has been shown to increase plasma levels of nitric oxide and decrease endothelin-1 levels, in some [82–84], but not in all studies [85]. In vitro estrogen increases nitric oxide production in endothelial cells [86], mRNA for nitric oxide synthase [87] and prostacyclin production [88,89], while estrogen decreases [90] or has no effect [88] on endothelin-1 production. The rapid non-genomic estrogen-mediated vasodilatory effects are thought to be mediated mainly via ion-channel function and nitric oxide. In endothelial cells, estrogen has been shown to regulate nitric oxide release by rapid activation of endothelial nitric oxide synthase [91], whereas in smooth muscle cells, estrogen opens calcium-activated potassium channels [92], thus producing vasodilatation. Recently it was shown that 17β-estradiol interacts directly with the regulatory β subunit of Maxi-K potassium channels on vascular smooth muscle cells [93], thus demonstrating a novel way for estrogen to modulate rapidly vascular wall function.

Another potential site of an estrogen direct vascular action is the uptake and metabolism of LDL cholesterol by cells of the artery wall since increased arterial LDL cholesterol accumulation and degradation are shown to be early events in the atherogenic process [94,95] (Fig. 5). In a study with ovariectomized cynomolgus monkeys, Wagner et al. [96] conducted an 18-week study wherein the animals were given parenterally physiologic doses of 17β-estradiol and cyclic progesterone. The relatively short duration of the experiment was designed to allow investigation of the effects of the treatment on arterial LDL cholesterol metabolism in the earliest stages of the pathogenesis of atheroslcerotic lesions. The degradation and accumulation of LDL cholesterol in coronary arteries were measured using radiolabeled LDL particles. Animals receiving hormone treatment had about a 70% reduction, compared to control animals, in degradation products following accumulation of LDL in the coronary arteries, while the plasma lipid, lipoprotein and apoprotein concentrations were not affected. A subsequent 16-week study, using the same techniques, determined the effects of oral esterified estrogens with and without methyltestosterone on LDL cholesterol metabolism [97]. Again, there was about a 70% reduction in coronary artery LDL cholesterol accumulation associated with the hormone treatments. In contrast to the previous study where parenteral hormone treatment did not affect lipoprotein concentrations [96], the use of oral estrogens resulted in reduced apolipoprotein B-containing lipoprotein concentrations and smaller LDL particle size [97]. In a third study using oral contraceptives, regardless of the adverse effects on plasma lipoprotein concentrations, arterial LDL accumulation was also reduced by approximately 70% [98]. Thus, these studies suggest that the estrogen-induced reduction in arterial LDL cholesterol accumulation is independent of plasma lipoprotein concentration. Although estrogens appear to limit retention of lipoproteins in the arterial wall, studies on the effect of estrogens on the vascular wall permeability are controversial [99,100]. Thus, the exact mechanism behind this estrogen-induced reduction in arterial LDL degradation and accumulation is unclear.


Figure 5
View larger version (26K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 5 In experiments using surgically postmenopausal cynomolgus monkeys, hormone replacement therapy significantly decreased LDL (low-density lipoprotein) uptake in the coronary arteries [96].

 

   7. Are the cardiovascular benefits of estrogen replacement therapy modulated by inflammation?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
8. Are there any...
 9. What are the...
 10. Conclusions
 References
 
Atherosclerosis is a chronic inflammatory condition of the vascular wall that is converted to an acute clinical event by the induction of plaque rupture leading to thrombosis [101]. Several plasma markers of inflammation, such as high-sensitivity C-reactive protein (CRP), cytokines and different soluble adhesion molecules, have been evaluated as potential tools for predicting the risk of cardiovascular disease in women [102]. The association of CRP and ERT was first reported from a study comparing levels of inflammation variables among elderly women (mean age over 72 years) using unopposed estrogen (n=230, years of use 18.4±11.6) or estrogen/progestin (n=60, years of use 12.0±9.0), with nonusers (n=196) [103]. In this cross-sectional study, CRP levels, compared to controls, were about 60% higher among women using unopposed estrogen, without a change in women using estrogen/progestin. However, use of unopposed estrogen was associated with lower levels of two other inflammation markers, fibrinogen and alpha-1 acid glycoprotein [103]. These results were confirmed from another cross-sectional survey of 493 healthy postmenopausal women (mean age 51 years) showing median CRP levels two times higher among women using unopposed estrogen or estrogen plus progesterone compared to nonusers [104]. Furthermore, similar findings were reported from the PEPI trial, where relative to placebo, when combining the active treatment arms, final concentrations of CRP were 85% higher, while the adhesion molecule E-selectin was 18% lower compared with baseline [105]. In contrast, a later report from a double-blind trial of 33 women with type 2 diabetes, a combination of transdermal estradiol (80 µg) and continuous oral norethisterone (1 mg) significantly reduced CRP concentrations relative to placebo after 6 months of therapy [106]. Synthesis of CRP in the liver is primarily regulated by interleukin-6, and the plasma levels of interleukin-6 were shown to be lower among women using hormone replacement therapy compared to nonusers [107]. Although the clinical relevance of the effect of ERT on CRP remains unclear, it is possible that the CRP-raising effect of oral ERT is related to first-pass liver effects on CRP production, rather than cytokine-dependent changes in CRP.

Estrogen replacement therapy has been shown to reduce plasma concentrations of the adhesion molecules, E-selectin, vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [54,105,108–110]. Reduction of these vascular adhesion molecules could be potentially atheroprotective by reducing the attachment of white blood cells to the vessel wall. However, one study which reported reduction in the E-selectin, VCAM-1 and ICAM-1 levels, showed at the same time that estrogen may increase the expression of matrix metalloproteinase-9 [110], activation of which could digest fibrous caps of vulnerable plaques, resulting in thrombosis. A recent study on the histologic features of coronary plaques in pre- and postmenopausal women who died from noncoronary causes implies that the anti-inflammatory effect of estrogen results in plaque stabilization, but does not appear to inhibit plaque erosion [111]. Furthermore, in vitro studies investigating the effects of 17β-estradiol on the cytokine-activated endothelial cell adhesion molecules show opposite results [112,113]. Taken together, it seems that several markers of inflammation can be modulated by ERT, but the meaning of these divergent findings remains to be determined.


   8. Are there any cardiovascular benefits to be derived from synthetic or natural selective estrogen receptor modulators (i.e. raloxifene or phytoestrogens), or compounds with selective steroid actions (i.e. tibolone)?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
9. What are the...
 10. Conclusions
 References
 
The majority of postmenopausal women choose not to undergo traditional ERT [114], primarily due to the fact that both CEE and 17β-estradiol are estrogen agonist for all target organs and thus, can pose a potential cancer risk for the breast and endometrium. Current research seeks to identify estrogen substitutes exerting estrogen agonist or antagonist actions on different tissues, compounds that are referred to as selective estrogen receptor modulators (SERMs) [115]. Some compounds, such as tamoxifen, have been in use for many years. Tamoxifen is used in the treatment of breast cancer since it has estrogen antagonist effects on breast, while acting as an estrogen agonist for endometrium, arteries and bone. In the Scottish breast cancer trial, the incidence of fatal myocardial infarction was 63% less in patients who received tamoxifen compared to those who did not [116]. The follow-up of this study, where the women were up to 14 years on tamoxifen show similar results [117]. However, the Breast Cancer Prevention Trial, the only one carried out in women who did not have a diagnosis of breast cancer, did not show differences in the rate for ischemic heart disease between women in the tamoxifen group compared to placebo controls [118]. The effect of tamoxifen, compared with CEE treatment, on coronary artery atherosclerosis [119] and vascular reactivity [120] was investigated in cynomolgus monkeys. While CEE treatment was associated with approximately 70% inhibition of coronary artery atherosclerosis, the effect of tamoxifen treatment was intermediate between the CEE treatment and no treatment. The coronary artery reactivity following in vivo acetylcholine infusion showed that CEE acted as an estrogen agonist with dilation of the coronary arteries, while tamoxifen acted as an antiestrogen, inducing paradoxical constriction. These results imply mixed estrogenic–antiestrogenic effects of tamoxifen on coronary arteries. It is also possible that atherosclerosis inhibition and vascular reactivity are mediated by different estrogen receptors, which is supported by a study showing that tamoxifen has partial agonist effects with ER-{alpha} but not with ER-β in human vascular smooth muscle cells [64].

Raloxifene is a more recently discovered synthetic SERM that has estrogen agonist effects on bone and plasma cholesterol concentrations, but estrogen antagonist effects on breast and uterus [121]. Raloxifene treatment of postmenopausal women has a modest lowering effect on plasma concentrations of LDL cholesterol and no effect on HDL cholesterol [121,122]. The effect of raloxifene on coronary artery atherosclerosis compared with CEE treatment has been investigated in a randomized trial using surgically postmenopausal cynomolgus monkeys [28]. In that study, raloxifene reduced LDL cholesterol concentrations and had no significant effect on HDL cholesterol, quite comparable to raloxifene effects on women [121,122]. However, neither the low nor the high dose of raloxifene had an effect on coronary artery atherosclerosis, while CEE treatment resulted in about 70% reduction in coronary artery atherosclerosis [28]. At a recent meeting of the American College of Cardiology, an interim report based on three years of raloxifene treatment in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial was presented. The MORE trial enrolled 7705 postmenopausal women (mean age 67 years) with osteoporosis that were randomized to placebo or raloxifene at a daily dose of 60 mg or 120 mg. The study showed no effect of either 60 mg or 120 mg dose of raloxifene treatment on any cardiovascular events (relative risk, 0.89; CI, 0.64–1.25 and 1.00; CI, 0.72–1.39, respectively). For coronary events relative risk was 0.88 (CI, 0.56–1.39) at the 60 mg dose and 1.10 (CI, 0.72–1.70) at the 120 mg dose. Thus, these results do not indicate that raloxifene would share the same cardioprotective properties as estrogens.

Phytoestrogens are a group of natural compounds derived from plants, primarily from legumes. Phytoestrogens share structural similarities with 17β-estradiol and exert both estrogen agonist and antagonist properties [123], thus phytoestrogens could be considered as natural SERMs. This could be partly explained by the fact that phytoestrogens are shown to have different binding affinities to the estrogen receptors [124]. For example, the binding affinity of the soy-derived phytoestrogen genistein for ER-{alpha} is only 4%, whereas its affinity for ER-β was 87% compared to 17β-estradiol. Given the different tissue distribution of the ER-{alpha} and ER-β [63,125], there is a basis for tissue-selective effects of the phytoestrogens.

There is growing evidence from epidemiological [126] and experimental [30,127] studies that consumption of phytoestrogens has a beneficial effect on the risk of coronary heart disease. Soy protein intake is associated with approximately 10–13% reduction in plasma triglyceride and LDL cholesterol, and a slight increase in HDL cholesterol [128]. Similar results on LDL and HDL cholesterol were shown in a study with postmenopausal cynomolgus monkeys fed a moderately atherogenic diet where the primary source of protein was casein or soy protein [127]. In this study the soy protein-fed animals had 90% less atherosclerosis compared to the casein-fed animals. In another more recent study of 36 months duration, cynomolgus monkeys were fed soy protein, or soy protein that had been alcohol-washed to remove the soy phytoestrogens (control), and these groups were compared to CEE-treated animals [30]. The effect of soy phytoestrogens on LDL and HDL cholesterol was similar to results shown before [127]. CEE treatment reduced coronary artery atherosclerosis about 50%, while in animals treated with soy phytoestrogens, the reduction was intermediate between the control and CEE treatment [30]. Interestingly, the treatment with soy phytoestrogens was comparable to CEE in reducing common carotid and internal carotid artery atherosclerosis [30] (Fig. 6). Soy protein isolate, containing its phytoestrogens, has been shown to also lower diastolic blood pressure in women [129,130], and improve vascular reactivity and endothelial function in humans and non-human primates [131,132].


Figure 6
View larger version (29K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 6 Effects of SPE and CEE treatments on coronary artery atherosclerotic plaque extent (panel a) and on extent of internal carotid artery atherosclerosis (panel b). Data presented are the mean±S.E.M. [30]. SPE, soy phytoestrogens; and CEE, conjugated equine estrogen.

 
Tibolone is a synthetic steroid possessing estrogenic, progestogenic, and androgenic action [133]. Clinically, tibolone has been shown to be effective for the treatment of climacteric symptoms [134] and for the prevention of postmenopausal osteoporosis [135], without proliferative effects on the endometrium [136]. The selective steroid actions of tibolone are due to metabolites of tibolone; 3{alpha}-OH and 3β-OH metabolites having estrogenic effects, and the {Delta}4-isomer having progestogenic and androgenic effects. The {Delta}4-isomer, produced primarily within the endometrium, protects the endometrium from the agonist effects of the two estrogenic metabolites [136]. Tibolone treatment in postmenopausal women reduces plasma triglyceride [137] and Lp(a) [138] concentrations, with little effect on LDL. However, concern that tibolone may be atherogenic has arisen because tibolone also reduces plasma HDL cholesterol concentrations by approximately 30% [139]. In postmenopausal women the long-term vascular effects of tibolone has not been evaluated, but recently Clarkson, et al. [29] concluded a study in postmenopausal cynomolgus monkeys comparing the effect of tibolone and ERT on coronary artery atherosclerosis. In this study, the animals were treated for 2 years with CEE alone or combined with MPA, or tibolone at two doses comparable to women taking 1.25–2.5 mg/day, or no treatment. Despite the fact that tibolone reduced plasma HDL cholesterol concentrations similar to or greater than that seen in women, there was no increase in coronary artery atherosclerosis. Furthermore, with a 30% reduction in HDL cholesterol concentrations there was no reduction in the serum cholesterol efflux potential, and thus, no indication for adverse effects of tibolone treatment on reverse cholesterol transport [140]. Our results imply that although tibolone does not share CEE's benefits on coronary artery atherosclerosis, there is no indication that the effects of tibolone on plasma lipoprotein concentrations are associated with an increase in atherosclerosis.


   9. What are the future directions in estrogen replacement therapy?
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
10. Conclusions
 References
 
9.1. Early initiation of ERT
As reviewed above, there is a substantial body of observational and experimental data to support the beneficial effects of ERT on prevention of cardiovascular disease. Whether WHI will confirm these findings remains to be seen in 2005 when this study with large expectations is completed. However, it is possible that the ERT-mediated cardiovascular protection does not apply at later stages of atherosclerosis, as shown by the randomized human [25,26] and non-human primate [31] studies. The preliminary data from WHI may indicate that the age (stage of atherosclerosis) and complexity of atherosclerotic lesions will be nonresponsive to estrogen treatment. This would imply that it is important for healthy women to start ERT immediately after menopause in order to maintain the estrogen-mediated cardiovascular benefits. Since conventional ERT is not acceptable to the majority of postmenopausal women, mainly because of the fear of cancer, the challenge is to search for new regimens or modify conventional ERT to obtain a better overall risk profile.

9.2. Lower doses of estrogens
The most recent update on the Nurses' Health Study shows that women taking oral CEE, either 0.625 or 0.3 mg, were both associated with a reduced risk for heart disease [16]. However, there was an increase in risk for stroke among women taking CEE 0.625 mg (relative risk, 1.35; CI, 1.08–1.68), or 1.25 mg or more (relative risk, 1.63; CI, 1.18–2.26). These findings would strongly recommend the use of a lower CEE dose, which could theoretically also reduce the ERT-associated cancer risk.

9.3. Combinations of ERT with SERMs
Since the SERMs so far have not fulfilled the expectations as the ‘ideal’ hormone replacement, an intriguing possibility is to combine SERMs with low-dose estrogen. Support for this comes from animal studies where soy phytoestrogens are combined with estrogens. In cynomolgus monkeys, soy phytoestrogen treatment showed antiproliferative effects in the endometrium and mammary gland when combined with 17β-estradiol [141]. Similar results on mammary gland were shown in a more recent study with ovariectomized rats when treated with soy phytoestrogens combined with CEE [142]. Furthermore, in cynomolgus monkeys, soy phytoestrogens combined with 17β-estradiol showed additive effects in reducing arterial cholesterol content and improvement in vascular reactivity [143]. Taken together, these results imply that combining soy phytoestrogens with estrogens may protect breast and endometrial tissues while having additive beneficial effect on cardiovascular protection. These findings provide encouragement for further studies with other combined therapies.


   10. Conclusions
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
References
 
Despite disappointing outcomes from trials to evaluate estrogen treatment on postmenopausal cardiovascular disease, there is considerable evidence to support the beneficial effects of estrogens in the early stages of atherogenesis (during the menopausal transition and the early years of postmenopause). Lack of compliance with ERT, usually because of fear of breast cancer, remains a major problem. Future regimens may overcome that fear by the co-administration of a breast cancer preventive agent (i.e. SERMs, phytoestrogens) with low dose estrogen.

Time for primary review 46 days.


   References
Top
 Abstract
 1. Introduction
 2. What is the...
 3. What is the...
 4. Are the cardiovascular...
 5. Are the cardiovascular...
 6. What are the...
 7. Are the cardiovascular...
 8. Are there any...
 9. What are the...
 10. Conclusions
 References
 

  1. Isles C.G., Hole D.J., Hawthorne V.M., Lever A.F. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men. Lancet (1992) 339:702–706.[CrossRef][Web of Science][Medline]
  2. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. J Am Med Assoc (1991) 265:1861–1867.[Abstract/Free Full Text]
  3. Maxwell S.R. Women and heart disease. Basic Res Cardiol (1998) 93(Suppl_2):79–84.[CrossRef][Web of Science][Medline]
  4. Kannel W.B., Hjortland M.C., McNamara P.M., Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med (1976) 85:447–452.[Abstract/Free Full Text]
  5. McKinlay S.M., Bifano N.L., McKinlay J.B. Smoking and age at menopause in women. Ann Intern Med (1985) 103:350–356.[Abstract/Free Full Text]
  6. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. N Engl J Med (1987) 316:1105–1110.[Abstract]
  7. Hu F.B., Grodstein F., Hennekens C.H., et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med (1999) 159:1061–1066.[Abstract/Free Full Text]
  8. Jacobsen B.K., Nilssen S., Heuch I., Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J Clin Epidemiol (1997) 50:475–479.[CrossRef][Web of Science][Medline]
  9. van der Schouw Y.T., van der Graaf G.Y., Steyerberg E.W., Eijkemans J.C., Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet (1996) 347:714–718.[CrossRef][Web of Science][Medline]
  10. Joakimsen O., Bonaa K.H., Stensland-Bugge E., Jacobsen B.K. Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromso Study. J Clin Epidemiol (2000) 53:525–530.[CrossRef][Web of Science][Medline]
  11. Grady D., Rubin S.M., Petitti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med (1992) 117:1016–1037.[Abstract/Free Full Text]
  12. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health (1998) 19:55–72.[CrossRef][Web of Science][Medline]
  13. Stampfer M.J., Willett W.C., Colditz G.A., Rosner B., Speizer F.E., Hennekens C.H. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med (1985) 313:1044–1049.[Abstract]
  14. Stampfer M.J., Colditz G.A., Willett W.C., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 325:756–762.[Abstract]
  15. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med (1996) 335:453–461.[Abstract/Free Full Text]
  16. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med (2000) 133:933–941.[Abstract/Free Full Text]
  17. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol (1996) 143:971–978.[Abstract/Free Full Text]
  18. Petitti D.B. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol (1994) 4:115–118.[Medline]
  19. Gallagher E.J., Viscoli C.M., Horwitz R.I. The relationship of treatment adherence to the risk of death after myocardial infarction in women. J Am Med Assoc (1993) 270:742–744.[Abstract/Free Full Text]
  20. Coronary Drug Project. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038–1041.
  21. Ylikorkala O. Balancing between observational studies and randomized trials in prevention of coronary heart disease by estrogen replacement: HERS study was no revolution. Acta Obstet Gynecol Scand (2000) 79:1029–1036.[CrossRef][Web of Science][Medline]
  22. Clarkson T.B., Anthony M.S., Klein K.P. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynaecol (1996) 103(Suppl 13):53–57.[Web of Science][Medline]
  23. Adams M.R., Kaplan J.R., Manuck S.B., et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis (1990) 10:1051–1057.[Abstract/Free Full Text]
  24. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 17:217–221.[Abstract/Free Full Text]
  25. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc (1998) 280:605–613.[Abstract/Free Full Text]
  26. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med (2000) 343:522–529.[Abstract/Free Full Text]
  27. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61–109.
  28. Clarkson T.B., Anthony M.S., Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab (1998) 83:721–726.[Abstract/Free Full Text]
  29. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab, in press.
  30. Clarkson T.B., Anthony M.S., Morgan T.M. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab (2001) 86:41–47.[Abstract/Free Full Text]
  31. Williams J.K., Anthony M.S., Honore E.K., et al. Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol (1995) 15:827–836.[Abstract/Free Full Text]
  32. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet (1997) 349:458–461.[CrossRef][Web of Science][Medline]
  33. Falkeborn M., Persson I., Adami H.O., et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol (1992) 99:821–828.[Web of Science][Medline]
  34. Psaty B.M., Heckbert S.R., Atkins D., et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med (1994) 154:1333–1339.[Abstract/Free Full Text]
  35. Cline J.M., Anthony M.S., Register T.C., Borgerink H., Clarkson T.B. Tibolone does not stimulate the endometrium or breast in cynomolgus monkeys. FASEB J (2001) 15:A594.
  36. Heiss G., Tamir I., Davis C.E., et al. Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation (1980) 61:302–315.[Free Full Text]
  37. Connelly P.W., MacLean D.R., Horlick L., O'Connor B., Petrasovits A., Little J.A. Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in Canadian adults. Canadian Heart Health Surveys Research Group. Can Med Assoc J (1992) 146:1977–1987.[Abstract]
  38. Kannel W.B., Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med (1995) 155:57–61.[Abstract/Free Full Text]
  39. Stevenson J.C., Crook D., Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis (1993) 98:83–90.[CrossRef][Web of Science][Medline]
  40. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med (1991) 325:1196–1204.[Abstract]
  41. Nabulsi A.A., Folsom A.R., White A., et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med (1993) 328:1069–1075.[Abstract/Free Full Text]
  42. Brinton E.A. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol (1996) 16:431–440.[Abstract/Free Full Text]
  43. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199–208.
  44. Orth-Gomer K., Mittleman M.A., Schenck-Gustafsson K., et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation (1997) 95:329–334.[Abstract/Free Full Text]
  45. Espeland M.A., Marcovina S.M., Miller V., et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation (1998) 97:979–986.[Abstract/Free Full Text]
  46. Ylikorkala O., Lim P., Caubel P. Effects on serum lipid profiles of continuous 17-beta-estradiol, intermittent norgestimate regimens versus continuous combined 17-beta-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther (2000) 22:622–636.[CrossRef][Web of Science][Medline]
  47. Lindgren R., Berg G., Hammar M., Larsson-Cohn U., Olsson A.G. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. Eur J Obstet Gynecol Reprod Biol (1992) 47:213–221.[CrossRef][Web of Science][Medline]
  48. Crook D., Cust M.P., Gangar K.F., et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol (1992) 166:950–955.[Web of Science][Medline]
  49. Whitehead M.I., Fraser D., Schenkel L., Crook D., Stevenson J.C. Transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet (1990) 335:310–312.[CrossRef][Web of Science][Medline]
  50. Chetkowski R.J., Meldrum D.R., Steingold K.A., et al. Biologic effects of transdermal estradiol. N Engl J Med (1986) 314:1615–1620.[Abstract]
  51. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
  52. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med (1995) 333:1301–1307.[Abstract/Free Full Text]
  53. Darling G.M., Johns J.A., McCloud P.I., Davis S.R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med (1997) 337:595–601.[Abstract/Free Full Text]
  54. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation (1999) 99:354–360.[Abstract/Free Full Text]
  55. Wakatsuki A., Okatani Y., Ikenoue N. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis (2000) 150:103–111.[CrossRef][Web of Science][Medline]
  56. Herrington D.M., Werbel B.L., Riley W.A., Pusser B.E., Morgan T.M. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol (1999) 33:2030–2037.[Abstract/Free Full Text]
  57. Bush T.L., Barrett-Connor E., Cowan L.D., et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 75:1102–1109.[Abstract/Free Full Text]
  58. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med (1999) 340:1801–1811.[Free Full Text]
  59. Walter P., Green S., Greene G., et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA (1985) 82:7889–7893.[Abstract/Free Full Text]
  60. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA (1996) 93:5925–5930.[Abstract/Free Full Text]
  61. Karas R.H., Patterson B.L., Mendelsohn M.E. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation (1994) 89:1943–1950.[Abstract/Free Full Text]
  62. Venkov C.D., Rankin A.B., Vaughan D.E. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation (1996) 94:727–733.[Abstract/Free Full Text]
  63. Mäkelä S., Savolainen H., Aavik E., et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci USA (1999) 96:7077–7082.[Abstract/Free Full Text]
  64. Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation (2000) 101:1792–1798.[Abstract/Free Full Text]
  65. Register T.C., Adams M.R. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol (1998) 64:187–191.[CrossRef][Web of Science][Medline]
  66. Iafrati M.D., Karas R.H., Aronovitz M., et al. Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nature Med (1997) 3:545–548.[CrossRef][Web of Science][Medline]
  67. Karas R.H., Hodgin J.B., Kwoun M., et al. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci USA (1999) 96:15133–15136.[Abstract/Free Full Text]
  68. Hodgin J.B., Krege J.H., Reddick R.L., Korach K.S., Smithies O., Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe–/– mice. J Clin Invest (2001) 107:333–340.[Web of Science][Medline]
  69. Sudhir K., Chou T.M., Messina L.M., et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet (1997) 349:1146–1147.[CrossRef][Web of Science][Medline]
  70. Sudhir K., Chou T.M., Chatterjee K., et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation (1997) 96:3774–3777.[Abstract/Free Full Text]
  71. Austin C.E. Chronic and acute effects of oestrogens on vascular contractility. J Hypertens (2000) 18:1365–1378.[CrossRef][Web of Science][Medline]
  72. Williams J.K., Adams M.R., Klopfenstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation (1990) 81:1680–1687.[Abstract/Free Full Text]
  73. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol (1992) 20:452–457.[Abstract]
  74. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol (1994) 73:951–952.[CrossRef][Web of Science][Medline]
  75. Reis S.E., Gloth S.T., Blumenthal R.S., et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation (1994) 89:52–60.[Abstract/Free Full Text]
  76. Gilligan D.M., Quyyumi A.A., Cannon R.O. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation (1994) 89:2545–2551.[Abstract/Free Full Text]
  77. Lieberman E.H., Gerhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med (1994) 121:936–941.[Abstract/Free Full Text]
  78. Al-Khalili F., Eriksson M., Landgren B.M., Schenck-Gustafsson K. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol (1998) 82:215–218.[CrossRef][Web of Science][Medline]
  79. Higashi Y., Sanada M., Sasaki S., et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension (2001) 37:651–657.[Abstract/Free Full Text]
  80. Cacciatore B., Paakkari I., Toivonen J., Tikkanen M.J., Ylikorkala O. Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow. Obstet Gynecol (1998) 92:563–568.[CrossRef][Web of Science][Medline]
  81. Mikkola T., Viinikka L., Ylikorkala O. Estrogen and postmenopausal estrogen/progestin therapy: effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol (1998) 79:75–82.[CrossRef][Web of Science][Medline]
  82. Ylikorkala O., Orpana A., Puolakka J., Pyorala T., Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab (1995) 80:3384–3387.[Abstract]
  83. Best P.J., Berger P.B., Miller V.M., Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med (1998) 128:285–288.[Abstract/Free Full Text]
  84. Cicinelli E., Ignarro L.J., Matteo M.G., Galantino P., Schonauer L.M., Falco N. Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol (1999) 180:334–339.[CrossRef][Web of Science][Medline]
  85. Ylikorkala O., Cacciatore B., Paakkari I., Tikkanen M.J., Viinikka L., Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril (1998) 69:883–888.[CrossRef][Web of Science][Medline]
  86. Hayashi T., Yamada K., Esaki T., et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun (1995) 214:847–855.[CrossRef][Web of Science][Medline]
  87. MacRitchie A.N., Jun S.S., Chen Z., et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res (1997) 81:355–362.[Abstract/Free Full Text]
  88. Mikkola T., Turunen P., Avela K., Orpana A., Viinikka L., Ylikorkala O. 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells. J Clin Endocrinol Metab (1995) 80:1832–1836.[Abstract]
  89. Jun S.S., Chen Z., Pace M.C., Shaul P.W. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest (1998) 102:176–183.[Web of Science][Medline]
  90. Akishita M., Kozaki K., Eto M., et al. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem Biophys Res Commun (1998) 251:17–21.[CrossRef][Web of Science][Medline]
  91. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest (1999) 103:401–406.[Web of Science][Medline]
  92. White R.E., Darkow D.J., Lang J.L. Estrogen relaxes coronary arteries by opening BKCa channels through a cGMP-dependent mechanism. Circ Res (1995) 77:936–942.[Abstract/Free Full Text]
  93. Valverde M.A., Rojas P., Amigo J., et al. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. Science (1999) 285:1929–1931.[Abstract/Free Full Text]
  94. Schwenke D.C., Carew T.E. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis (1989) 9:895–907.[Abstract/Free Full Text]
  95. St. Clair R.W. Pathogenesis of atherosclerosis. Cardiol Rev (1997) 5:14–24.[Medline]
  96. Wagner J.D., Clarkson T.B., StClair R.W., Schwenke D.C., Shively C.A., Adams M.R. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest (1991) 88:1995–2002.[Web of Science][Medline]
  97. Wagner J.D., Zhang L., Williams J.K., et al. Esterified estrogens with and without methyltestosterone decrease arterial LDL metabolism in cynomolgus monkeys. Arterioscler Thromb Vasc Biol (1996) 16:1473–1480.[Abstract/Free Full Text]
  98. Wagner J.D., Adams M.R., Schwenke D.C., Clarkson T.B. Oral contraceptive treatment decreases arterial low density lipoprotein degradation in female cynomolgus monkeys. Circ Res (1993) 72:1300–1307.[Abstract/Free Full Text]
  99. Walsh B.A., Mullick A.E., Banka C.E., Rutledge J.C. 17beta-estradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation. J Lipid Res (2000) 41:134–141.[Abstract/Free Full Text]
  100. Haarbo J., Nielsen L.B., Stender S., Christiansen C. Aortic permeability to LDL during estrogen therapy–a study in normocholesterolemic rabbits. Arterioscler Thromb (1994) 14:243–247.[Abstract/Free Full Text]
  101. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med (1999) 340:115–126.[Free Full Text]
  102. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 342:836–843.[Abstract/Free Full Text]
  103. Cushman M., Meilahn E.N., Psaty B.M., Kuller L.H., Dobs A.S., Tracy R.P. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol (1999) 19:893–899.[Abstract/Free Full Text]
  104. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation (1999) 100:713–716.[Abstract/Free Full Text]
  105. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. Circulation (1999) 100:717–722.[Abstract/Free Full Text]
  106. Sattar N., Perera M., Small M., Lumsden M.A. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet (1999) 354:487–488.[CrossRef][Web of Science][Medline]
  107. Straub R.H., Hense H.W., Andus T., Scholmerich J., Riegger G.A., Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab (2000) 85:1340–1344.[Abstract/Free Full Text]
  108. Caulin-Glaser T., Farrell W.J., Pfau S.E., et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol (1998) 31:1555–1560.[Abstract/Free Full Text]
  109. Van Baal W.M., Emeis J.J., Kenemans P., et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest (1999) 29:913–921.[CrossRef][Web of Science][Medline]
  110. Zanger D., Yang B.K., Ardans J., et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol (2000) 36:1797–1802.[Abstract/Free Full Text]
  111. Burke A.P., Farb A., Malcom G., Virmani R. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis. Am Heart J (2001) 141(2):58–62.[CrossRef]
  112. Cid M.C., Kleinman H.K., Grant D.S., Schnaper H.W., Fauci A.S., Hoffman G.S. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest (1994) 93:17–25.[Web of Science][Medline]
  113. Caulin-Glaser T., Watson C.A., Pardi R., Bender J.R. Effects of 17beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest (1996) 98:36–42.[Web of Science][Medline]
  114. Brett K.M., Madans J.H. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol (1997) 145:536–545.[Abstract/Free Full Text]
  115. Cosman F., Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev (1999) 20:418–434.[Abstract/Free Full Text]
  116. McDonald C.C., Stewart H.J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J (1991) 303:435–437.[Abstract/Free Full Text]
  117. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., Stewart H.J. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J (1995) 311:977–980.[Abstract/Free Full Text]
  118. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 90:1371–1388.[Abstract/Free Full Text]
  119. Williams J.K., Wagner J.D., Li Z., Golden D.L., Adams M.R. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol (1997) 17:403–408.[Abstract/Free Full Text]
  120. Williams J.K., Honoré E.K., Adams M.R. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. Circulation (1997) 96:1970–1975.[Abstract/Free Full Text]
  121. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 337:1641–1647.[Abstract/Free Full Text]
  122. Walsh B.W., Kuller L.H., Wild R.A., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc (1998) 279:1445–1451.[Abstract/Free Full Text]
  123. Tikkanen M.J., Adlercreutz H. Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention? Biochem Pharmacol (2000) 60:1–5.[CrossRef][Web of Science][Medline]
  124. Kuiper G.G., Lemmen J.G., Carlsson B., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology (1998) 139:4252–4263.[Abstract/Free Full Text]
  125. Kuiper G.G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 138:863–870.[Abstract/Free Full Text]
  126. Vanharanta M., Voutilainen S., Lakka T.A., van der Lee L.M., Adlercreutz H., Salonen J.T. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet (1999) 354:2112–2115.[CrossRef][Web of Science][Medline]
  127. Anthony M.S., Clarkson T.B., Bullock B.C., Wagner J.D. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol (1997) 17:2524–2531.[Abstract/Free Full Text]
  128. Anderson J.W., Johnstone B.M., Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med (1995) 333:276–282.[Abstract/Free Full Text]
  129. Crouse J.R., Morgan T., Terry J.G., Ellis J., Vitolins M., Burke G.L. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med (1999) 159:2070–2076.[Abstract/Free Full Text]
  130. Washburn S., Burke G.L., Morgan T., Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause (1999) 6:7–13.[Web of Science][Medline]
  131. Honoré E.K., Williams J.K., Anthony M.S., Clarkson T.B. Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril (1997) 67:148–154.[CrossRef][Web of Science][Medline]
  132. Nestel P.J., Yamashita T., Sasahara T., et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol (1997) 17:3392–3398.[Abstract/Free Full Text]
  133. van der Vies J. Pharmacological studies with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org O.D. 14). Maturitas 1987;Suppl 1:15–24.
  134. Egarter C., Sator M., Berghammer P., Huber J. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet (1999) 64:281–286.[CrossRef][Medline]
  135. Bjarnason N.H., Bjarnason K., Haarbo J., Rosenquist C., Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 81:2419–2422.[Abstract]
  136. Genazzani A.R., Benedek-Jaszmann L.J., Hart D.M., Andolsek L., Kicovic P.M., Tax L. Org OD 14 and the endometrium. Maturitas (1991) 13:243–251.[CrossRef][Web of Science][Medline]
  137. Crona N., Silfverstolpe G., Samsioe G. A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol (1983) 102:451–455.[Medline]
  138. Rymer J., Crook D., Sidhu M., Chapman M., Stevenson J.C. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol (1993) 128:259–262.[Medline]
  139. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab (1997) 82:1752–1756.[Abstract/Free Full Text]
  140. Mikkola T.S., Anthony M.S., Clarkson T.B., St.Clair R.W. Cholesterol efflux potential of serum from atherogenic diet-fed cynomolgus monkeys after long-term tibolone treatment or traditional hormone replacement therapy. FASEB J (2001) 15:A248. (Abstract).
  141. Foth D., Cline J.M. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr (1998) 68:1413S–1417S.[Abstract]
  142. Paramastri Y.A., Anthony M.S., Wilkinson L.M., Phifer B.M., Cline J.M. Dietary soy phytoestrogens inhibit tumor promotion by exogenous but not endogenous estrogens in the rat DMBA model of mammary carcinogenesis. Proc Am Assoc Cancer Res (2001) 42:310.
  143. Wagner J.D., Cefalu W.T., Anthony M.S., Litwak K.N., Zhang L., Clarkson T.B. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism (1997) 46:698–705.[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
M. L. S. Gass, S. S. Bassuk, and J. E. Manson
Reassessing Benefits and Risks of Hormone Therapy
American Journal of Lifestyle Medicine, January 1, 2009; 3(1): 29 - 43.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
M. R. Sowers, J. Randolph Jr, M. Jannausch, B. Lasley, E. Jackson, and D. McConnell
Levels of Sex Steroid and Cardiovascular Disease Measures in Premenopausal and Hormone-Treated Women at Midlife: Implications for the "Timing Hypothesis"
Arch Intern Med, October 27, 2008; 168(19): 2146 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
B. Oneda, C. L. M. Forjaz, F. R. Bernardo, T. G. Araujo, J. L. Gusmao, E. Labes, S. B. Abrahao, D. Mion Jr., A. M. Fonseca, and T. Tinucci
Low-dose estrogen therapy does not change postexercise hypotension, sympathetic nerve activity reduction, and vasodilation in healthy postmenopausal women
Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1802 - H1808.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Vitale, G. Mercuro, E. Cerquetani, G. Marazzi, R. Patrizi, F. Pelliccia, M. Volterrani, M. Fini, P. Collins, and G. M.C. Rosano
Time Since Menopause Influences the Acute and Chronic Effect of Estrogens on Endothelial Function
Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 348 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. Rosenberg
RE: "INVITED COMMENTARY: HORMONE THERAPY AND RISK OF CORONARY HEART DISEASE WHY RENEW THE FOCUS ON THE EARLY YEARS OF MENOPAUSE?"
Am. J. Epidemiol., December 15, 2007; 166(12): 1480 - 1481.
[Full Text] [PDF]

Home page
 Am J EpidemiolHome page
J. E. Manson and S. S. Bassuk
Invited Commentary: Hormone Therapy and Risk of Coronary Heart Disease Why Renew the Focus on the Early Years of Menopause?
Am. J. Epidemiol., September 1, 2007; 166(5): 511 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
E. Barrett-Connor
Hormones and Heart Disease in Women: The Timing Hypothesis
Am. J. Epidemiol., September 1, 2007; 166(5): 506 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. H. Straub
The Complex Role of Estrogens in Inflammation
Endocr. Rev., August 1, 2007; 28(5): 521 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Sherwood, J. K. Bower, J. McFetridge-Durdle, J. A. Blumenthal, L. K. Newby, and A. L. Hinderliter
Age Moderates the Short-Term Effects of Transdermal 17{beta}-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women
Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1782 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. E. Manson, M. A. Allison, J. E. Rossouw, J. J. Carr, R. D. Langer, J. Hsia, L. H. Kuller, B. B. Cochrane, J. R. Hunt, S. E. Ludlam, et al.
Estrogen Therapy and Coronary-Artery Calcification
N. Engl. J. Med., June 21, 2007; 356(25): 2591 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Mendelsohn and R. H. Karas
HRT and the Young at Heart
N. Engl. J. Med., June 21, 2007; 356(25): 2639 - 2641.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev., June 1, 2007; 28(4): 387 - 439.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Moriarty, K. H. Kim, and J. R. Bender
Estrogen Receptor-Mediated Rapid Signaling
Endocrinology, December 1, 2006; 147(12): 5557 - 5563.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. H. Morrison, R. D. Brinton, P. J. Schmidt, and A. C. Gore
Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women
J. Neurosci., October 11, 2006; 26(41): 10332 - 10348.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise
Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies
Endocr. Rev., October 1, 2006; 27(6): 575 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Collins, M. Flather, B. Lees, R. Mister, A. J. Proudler, J. C. Stevenson, and on behalf of the WHISP (Women's Hormone Interventi
Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study
Eur. Heart J., September 1, 2006; 27(17): 2046 - 2053.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
Abstracts
Heart, February 1, 2006; 92(2): e1 - e1.
[Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
V. L. Ballard and J. M. Edelberg
Harnessing Hormonal Signaling for Cardioprotection
Sci. Aging Knowl. Environ., December 21, 2005; 2005(51): re6 - re6.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
V. M. Miller, T. B. Clarkson, S. M. Harman, E. A. Brinton, M. Cedars, R. Lobo, J. E. Manson, G. R. Merriam, F. Naftolin, and N. Santoro
Women, hormones, and clinical trials: a beginning, not an end
J Appl Physiol, August 1, 2005; 99(2): 381 - 383.
[Full Text] [PDF]

Home page
 Sci SignalHome page
K. H. Kim and J. R. Bender
Rapid, Estrogen Receptor-Mediated Signaling: Why Is the Endothelium So Special?
Sci. Signal., June 14, 2005; 2005(288): pe28 - pe28.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y.-M. Fan, P. Dastidar, H. Jokela, R. Punnonen, and T. Lehtimaki
Hepatic Lipase C-480T Genotype-Dependent Benefit from Long-Term Hormone Replacement Therapy for Atherosclerosis Progression in Postmenopausal Women
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3786 - 3792.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. K. Dubey, B. Imthurn, M. Barton, and E. K. Jackson
Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Cardiovasc Res, May 1, 2005; 66(2): 295 - 306.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Ropponen, K. Aittomaki, M. J. Tikkanen, and O. Ylikorkala
Levels of Serum C-Reactive Protein during Oral and Transdermal Estradiol in Postmenopausal Women with and without a History of Intrahepatic Cholestasis of Pregnancy
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 142 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Nakamura, K. Igarashi, T. Suzuki, J. Kanno, T. Inoue, C. Tazawa, M. Saruta, T. Ando, N. Moriyama, T. Furukawa, et al.
E4F1, a Novel Estrogen-Responsive Gene in Possible Atheroprotection, Revealed by Microarray Analysis
Am. J. Pathol., December 1, 2004; 165(6): 2019 - 2031.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. K. Dubey, B. Imthurn, L. C. Zacharia, and E. K. Jackson
Hormone Replacement Therapy and Cardiovascular Disease: What Went Wrong and Where Do We Go From Here?
Hypertension, December 1, 2004; 44(6): 789 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Helle, V. Lummaa, and J. Jokela
Accelerated immunosenescence in preindustrial twin mothers
PNAS, August 17, 2004; 101(33): 12391 - 12396.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
M. Stampfer
Commentary: Hormones and heart disease: do trials and observational studies address different questions?
Int. J. Epidemiol., June 1, 2004; 33(3): 454 - 455.
[Full Text] [PDF]

Home page
 Int J EpidemiolHome page
E. Barrett-Connor
Commentary: Observation versus intervention--what's different?
Int. J. Epidemiol., June 1, 2004; 33(3): 457 - 459.
[Full Text] [PDF]

Home page
 ScienceHome page
J. L. Turgeon, D. P. McDonnell, K. A. Martin, and P. M. Wise
Hormone Therapy: Physiological Complexity Belies Therapeutic Simplicity
Science, May 28, 2004; 304(5675): 1269 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
N. F. Col and S. G. Pauker
The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy
Ann Intern Med, May 4, 2004; 140(9): 765 - 766.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
F. Grodstein, J. E. Manson, M. J. Stampfer, and W. C. Willett
The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy
Ann Intern Med, May 4, 2004; 140(9): 764 - 765.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Akhrass, A. T. Evans, Y. Wang, S. Rich, C. R. Kannan, L. Fogelfeld, and T. Mazzone
Hormone Replacement Therapy Is Associated with Less Coronary Atherosclerosis in Postmenopausal Women
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5611 - 5614.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. Lokkegaard, Z. Jovanovic, B. L. Heitmann, N. Keiding, B. Ottesen, Y. A. Hundrup, E. B. Obel, and A. T. Pedersen
Increased Risk of Stroke in Hypertensive Women Using Hormone Therapy: Analyses Based on the Danish Nurse Study
Arch Neurol, October 1, 2003; 60(10): 1379 - 1384.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. C. Chappell, P. E. Gallagher, D. B. Averill, C. M. Ferrario, and K. B. Brosnihan
Estrogen or the AT1 Antagonist Olmesartan Reverses the Development of Profound Hypertension in the Congenic mRen2.Lewis Rat
Hypertension, October 1, 2003; 42(4): 781 - 786.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Barrett-Connor
An Epidemiologist Looks at Hormones and Heart Disease in Women
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Makela, P. Dastidar, H. Jokela, M. Saarela, R. Punnonen, and T. Lehtimaki
Effect of Long-Term Hormone Replacement Therapy on Atherosclerosis Progression in Postmenopausal Women Relates to Myeloperoxidase Promoter Polymorphism
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3823 - 3828.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. van Eickels, R. D. Patten, M. J. Aronovitz, A. Alsheikh-Ali, K. Gostyla, F. Celestin, C. Grohe, M. E. Mendelsohn, and R. H. Karas
17-Beta-Estradiol increases cardiac remodeling and mortality in mice with myocardial infarction
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2084 - 2092.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
F. Grodstein, J. E. Manson, and M. J. Stampfer
Postmenopausal Hormone Replacement Therapy
Ann Intern Med, April 15, 2003; 138(8): 688 - 688.
[Full Text] [PDF]

Home page
 CirculationHome page
K. B. Michels and J. E. Manson
Postmenopausal Hormone Therapy: A Reversal of Fortune
Circulation, April 15, 2003; 107(14): 1830 - 1833.
[Full Text] [PDF]

Home page
 Evid. Based Med.Home page
G. Colditz
Review: observational studies adjusting for socioeconomic status and lifestyle show no association between HRT and CAD
Evid. Based Med., March 1, 2003; 8(2): 46 - 46.
[Full Text] [PDF]

Home page
 Evid. Based Med.Home page
G. Colditz
Review: risks and benefits of HRT comparing various sources of evidence
Evid. Based Med., March 1, 2003; 8(2): 47 - 47.
[Full Text] [PDF]

Home page
 J. Physiol.Home page
K. L Moreau, A. J Donato, H. Tanaka, P. P. Jones, P. E Gates, and D. R Seals
Basal leg blood flow in healthy women is related to age and hormone replacement therapy status
J. Physiol., February 15, 2003; 547(1): 309 - 316.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Grodstein, T. B. Clarkson, and J. E. Manson
Understanding the Divergent Data on Postmenopausal Hormone Therapy
N. Engl. J. Med., February 13, 2003; 348(7): 645 - 650.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
D. H. Barlow
Time to reflect on the Women's Health Initiative (WHI) Study
Hum. Reprod., January 1, 2003; 18(1): 1 - 3.
[Full Text] [PDF]

Home page
 JAMAHome page
F. Grodstein and J. E. Manson
Relationship Between Hormone Replacement Therapy, Socioeconomic Status, and Coronary Heart Disease
JAMA, January 1, 2003; 289(1): 44 - 44.
[Full Text] [PDF]

Home page
 JAMAHome page
N. Radford, T. Church, F. E. Speizer, B. E. Pearson Murphy, S. R. Davis, H. G. Burger, W. H. Goodson III, H. R. Franke, I. Lev, A. Lahad, et al.
Risks of Postmenopausal Hormone Replacement
JAMA, December 11, 2002; 288(22): 2819 - 2824.
[Full Text] [PDF]

Home page
 Reproductive SciencesHome page
L. Speroff
The Impact of the Women's Health Initiative on Clinical Practice
Reproductive Sciences, September 1, 2002; 9(5): 251 - 253.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mikkola, T. S
Right arrow Articles by Clarkson, T. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikkola, T. S
Right arrow Articles by Clarkson, T. B
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?